DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
-19.51%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$201M
AUM Growth
+$201M
(-17%)
Cap. Flow
+$14.1M
Cap. Flow
% of AUM
7.01%
Top 10 Holdings %
Top 10 Hldgs %
47.8%
Holding
87
New
12
Increased
27
Reduced
13
Closed
4
Top Buys
| 1 |
iShares Biotechnology ETF
IBB
|
$3.74M |
| 2 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$1.85M |
| 3 |
LOXO
Loxo Oncology, Inc
LOXO
|
$1.68M |
| 4 |
Viking Therapeutics
VKTX
|
$1.37M |
| 5 |
CNCE
Concert Pharmaceuticals, Inc.
CNCE
|
$1.33M |
Top Sells
| 1 |
BioCryst Pharmaceuticals
BCRX
|
$1.51M |
| 2 |
IMMU
Immunomedics Inc
IMMU
|
$1.37M |
| 3 |
Novavax
NVAX
|
$1.32M |
| 4 |
Kura Oncology
KURA
|
$1.29M |
| 5 |
IMDZ
Immune Design Corp.
IMDZ
|
$1.13M |
Sector Composition
| 1 | Healthcare | 88.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
LOXO
1
DELISTED
Loxo Oncology, Inc
LOXO
| $25.4M | 12.65% | 181,675 +12,000 | +7% | +$1.68M |
|
2
Stereotaxis
STXS
$261M
| $14.8M | 7.35% | 13,680,554 | – | – |
|
|
SAGE
3
DELISTED
Sage Therapeutics
SAGE
| $9.99M | 4.97% | 104,306 +5,000 | +5% | +$479K |
|
4
AtriCure
ATRC
$1.84B
| $9.75M | 4.85% | 318,729 +25,000 | +9% | +$765K |
|
|
NXTM
5
DELISTED
NxStage Medical Inc.
NXTM
| $8.93M | 4.44% | 312,119 +6,000 | +2% | +$172K |
|
|
6
iShares Biotechnology ETF
IBB
$5.6B
| $6.26M | 3.11% | 64,900 +38,800 | +149% | +$3.74M |
|
7
argenx
ARGX
$43.6B
| $5.6M | 2.79% | 58,300 -6,000 | -9% | -$576K |
|
|
ZGNX
8
DELISTED
Zogenix, Inc.
ZGNX
| $5.24M | 2.61% | 143,764 +5,500 | +4% | +$201K |
|
|
AERI
9
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $5.12M | 2.55% | 141,770 +9,000 | +7% | +$325K |
|
|
BPMC
10
DELISTED
Blueprint Medicines
BPMC
| $5M | 2.48% | 92,691 | – | – |
|
11
Ascendis Pharma
ASND
$11.8B
| $4.84M | 2.41% | 77,242 | – | – |
|
12
ProQR Therapeutics
PRQR
$237M
| $4.3M | 2.14% | 272,474 +12,138 | +5% | +$192K |
|
13
DexCom
DXCM
$29.5B
| $4.07M | 2.03% | 34,000 -3,000 | -8% | -$359K |
|
|
ALDR
14
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $4.06M | 2.02% | 396,013 | – | – |
|
15
Akebia Therapeutics
AKBA
$833M
| $3.96M | 1.97% | 715,538 +89,800 | +14% | +$497K |
|
16
Neurocrine Biosciences
NBIX
$13.8B
| $3.93M | 1.95% | 55,008 +14,000 | +34% | +$1,000K |
|
17
Galapagos
GLPG
$2.07B
| $3.82M | 1.9% | 41,609 +2,000 | +5% | +$183K |
|
|
18
BioCryst Pharmaceuticals
BCRX
$1.74B
| $3.75M | 1.86% | 464,415 -187,671 | -29% | -$1.51M |
|
|
ARNA
19
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $3.66M | 1.82% | 93,942 -4,605 | -5% | -$179K |
|
20
Indaptus Therapeutics
INDP
$7.19M
| $3.49M | 1.74% | 463,228 -73,772 | -14% | -$556K |
|
|
LMNX
21
DELISTED
Luminex Corp
LMNX
| $3.2M | 1.59% | 138,391 | – | – |
|
|
BHVN
22
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $2.96M | 1.47% | 80,000 +50,000 | +167% | +$1.85M |
|
|
FOMX
23
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $2.9M | 1.44% | 808,000 | – | – |
|
|
BLUE
24
DELISTED
bluebird bio
BLUE
| $2.68M | 1.33% | 27,000 +6,500 | +32% | +$645K |
|
|
CBAY
25
DELISTED
Cymabay Therapeutics
CBAY
| $2.62M | 1.3% | 332,511 +38,000 | +13% | +$299K |
|